- Home
- MREO vs PRTC Comparison
MREO vs PRTC Comparison
Compare MREO & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- PRTC
- Stock Information
- Founded
- MREO 2015
- PRTC 2015
- Country
- MREO United Kingdom
- PRTC United States
- Employees
- MREO N/A
- PRTC N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- MREO Health Care
- PRTC Health Care
- Exchange
- MREO Nasdaq
- PRTC Nasdaq
- Market Cap
- MREO 438.8M
- PRTC 413.5M
- IPO Year
- MREO N/A
- PRTC N/A
- Fundamental
- Price
- MREO $1.76
- PRTC $19.07
- Analyst Decision
- MREO Strong Buy
- PRTC Buy
- Analyst Count
- MREO 5
- PRTC 1
- Target Price
- MREO $7.20
- PRTC $45.00
- AVG Volume (30 Days)
- MREO 4.4M
- PRTC 3.4K
- Earning Date
- MREO 08-12-2025
- PRTC 08-27-2025
- Dividend Yield
- MREO N/A
- PRTC N/A
- EPS Growth
- MREO N/A
- PRTC N/A
- EPS
- MREO N/A
- PRTC 0.21
- Revenue
- MREO N/A
- PRTC $4,828,000.00
- Revenue This Year
- MREO N/A
- PRTC $35.98
- Revenue Next Year
- MREO $51.92
- PRTC $115.38
- P/E Ratio
- MREO N/A
- PRTC $8.64
- Revenue Growth
- MREO N/A
- PRTC 44.98
- 52 Week Low
- MREO $1.57
- PRTC $13.30
- 52 Week High
- MREO $5.02
- PRTC $25.00
- Technical
- Relative Strength Index (RSI)
- MREO 35.35
- PRTC 57.26
- Support Level
- MREO $1.65
- PRTC $18.16
- Resistance Level
- MREO $1.89
- PRTC $19.60
- Average True Range (ATR)
- MREO 0.15
- PRTC 0.43
- MACD
- MREO -0.03
- PRTC 0.10
- Stochastic Oscillator
- MREO 12.84
- PRTC 69.77
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.